These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31568799)

  • 1. Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection.
    Chou S; Wu J; Song K; Bo T
    Antiviral Res; 2019 Dec; 172():104616. PubMed ID: 31568799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing.
    Chou S; Watters M; Sinha R; Kleiboeker S
    Antiviral Res; 2021 Sep; 193():105139. PubMed ID: 34273445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants.
    Chou S; Watanabe J
    Antiviral Res; 2024 Feb; 222():105792. PubMed ID: 38163624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo.
    Chou S; Hakki M; Villano S
    Antiviral Res; 2012 Aug; 95(2):88-92. PubMed ID: 22664236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
    Chou S; Alain S; Cervera C; Chemaly RF; Kotton CN; Lundgren J; Papanicolaou GA; Pereira MR; Wu JJ; Murray RA; Buss NE; Fournier M
    J Infect Dis; 2024 Feb; 229(2):413-421. PubMed ID: 37506264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection.
    Chou S; Song K; Wu J; Bo T; Crumpacker C
    J Infect Dis; 2022 Sep; 226(4):576-584. PubMed ID: 32726419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
    Chou S
    Rev Med Virol; 2008; 18(4):233-46. PubMed ID: 18383425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.
    Santos Bravo M; Plault N; Sánchez Palomino S; Mosquera Gutierrez MM; Fernández Avilés F; Suarez Lledo M; Sabé Fernández N; Rovira M; Alain S; Marcos Maeso MÁ
    J Infect Dis; 2021 Sep; 224(6):1024-1028. PubMed ID: 33475730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance.
    Chou S; Wechel LC; Marousek GI
    J Infect Dis; 2007 Jul; 196(1):91-4. PubMed ID: 17538888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
    Chou S; Marousek GI
    J Virol; 2008 Jan; 82(1):246-53. PubMed ID: 17942550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.
    Chou S; Ercolani RJ; Marousek G; Bowlin TL
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3375-9. PubMed ID: 23650173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir.
    Boutolleau D; Burrel S; Agut H
    Antiviral Res; 2011 Jul; 91(1):32-5. PubMed ID: 21570426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
    Chou S
    Antimicrob Agents Chemother; 2009 Jan; 53(1):81-5. PubMed ID: 18981262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
    Drew WL; Miner RC; Marousek GI; Chou S
    J Clin Virol; 2006 Oct; 37(2):124-7. PubMed ID: 16962820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir.
    Chou S; Marousek GI; Senters AE; Davis MG; Biron KK
    J Virol; 2004 Jul; 78(13):7124-30. PubMed ID: 15194788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.
    Marfori JE; Exner MM; Marousek GI; Chou S; Drew WL
    J Clin Virol; 2007 Feb; 38(2):120-5. PubMed ID: 17157554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir.
    Strasfeld L; Lee I; Tatarowicz W; Villano S; Chou S
    J Infect Dis; 2010 Jul; 202(1):104-8. PubMed ID: 20504236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maribavir: a novel antiviral agent with activity against cytomegalovirus.
    Trofe J; Pote L; Wade E; Blumberg E; Bloom RD
    Ann Pharmacother; 2008 Oct; 42(10):1447-57. PubMed ID: 18698013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful oral treatment of Ganciclovir resistant cytomegalovirus with Maribavir in the context of primary immunodeficiency: First case report and review.
    Bright PD; Gompels M; Donati M; Johnston S
    J Clin Virol; 2017 Feb; 87():12-16. PubMed ID: 27987421
    [No Abstract]   [Full Text] [Related]  

  • 20. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient.
    Schubert A; Ehlert K; Schuler-Luettmann S; Gentner E; Mertens T; Michel D
    BMC Infect Dis; 2013 Jul; 13():330. PubMed ID: 23870704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.